Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: vaginal ring Clear all
Completed Phase 4 Interventional Results available

MENOPUR® Versus FOLLISTIM®

NCT00802360
View directory record Official record
Conditions
Infertility
Interventions
Menotropin, Progestrone vaginal insert, follitropin beta, Progesterone in oil, Ganirelix
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Pasadena, California • San Diego, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2011 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®

NCT00475553
View directory record Official record
Conditions
Breakthrough Bleeding, Breakthrough Spotting
Interventions
remove ring if bleeding or spotting occurs more than 5 days, If bleeding does not remove ring
Other
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Sep 23, 2026, 7:26 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial

NCT07260825
View directory record Official record
Conditions
Vulvodynia, Dyspareunia, Lichen Sclerosus of Vulva
Interventions
Estradiol 0.01% Vag Cream, testosterone 0.1% and estradiol 0.01% vaginal cream
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone

NCT02626208
View directory record Official record
Conditions
Suppression of Ovulation
Interventions
Nestorone®/Estradiol Contraceptive Vaginal Ring
Device
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
7
States / cities
Sacramento, California • New York, New York • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause

NCT04544475
View directory record Official record
Conditions
Genitourinary Syndrome of Menopause (GSM)
Interventions
Revaree, Estrace
Device · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Sep 23, 2026, 7:26 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

NCT01406197
View directory record Official record
Conditions
Preterm Labor
Interventions
Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
17 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 23, 2026, 7:26 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA

NCT07039591
View directory record Official record
Conditions
Contraceptive Usage
Interventions
Pro-type IVR
Device
Lead sponsor
Population Council
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308007
View directory record Official record
Conditions
Vaginal Infection
Interventions
Terconazole, Metronidazole, Terconazole/metronidazole
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain

NCT03692403
View directory record Official record
Conditions
Endometriosis-related Pain
Interventions
Quinagolide 360 µg, Quinagolide 720 µg, Quinagolide 1080 µg, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
43
States / cities
Mesa, Arizona • Little Rock, Arkansas • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products

NCT01813162
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% gel, Vaginal product
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
San Francisco, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

The Vaginal Health Trial

NCT02516202
View directory record Official record
Conditions
Atrophy of Vagina, Menopause, Dyspareunia (Female)
Interventions
Vagifem, Replens, Placebo tablet, Placebo gel
Drug · Device · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 23, 2026, 7:26 PM EDT
Not listed Phase 3 Interventional

Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy

NCT03782480
View directory record Official record
Conditions
Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions
Intrarosa, Placebos
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth

NCT02913495
View directory record Official record
Conditions
Premature Birth
Interventions
Vaginal Progesterone, Intramuscular Progesterone (17 alpha hydroxprogesterone caproate)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Springfield, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP

NCT02073734
View directory record Official record
Conditions
Pelvic Organ Prolapse, PONV
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 81 Years · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 23, 2026, 7:26 PM EDT
Terminated Phase 2 Interventional Results available

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333
View directory record Official record
Conditions
Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions
Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
Drug · Combination Product
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

NCT02010593
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dapivirine Vaginal Ring, Placebo Vaginal Ring
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 23, 2026, 7:26 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Application for the Etonogestrel/Ethinyl Estradiol Ring

NCT03120728
View directory record Official record
Conditions
Emergency Contraception, Healthy, Reproductive Age Women
Interventions
Etonogestrel/ethinyl estradiol contraceptive vaginal ring
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants

NCT02039323
View directory record Official record
Conditions
Healthy Adult Females
Interventions
Tenofovir, Maraviroc
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 1Phase 2 Interventional

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

NCT01020396
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Metronidazole
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
37
States / cities
Huntsville, Alabama • Fountain Valley, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Vaginal Progesterone to Reduce the Risk of Another Preterm Birth

NCT00086177
View directory record Official record
Conditions
Pregnancy
Interventions
8% progesterone vaginal gel, Placebo Vaginal Gel
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
636 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
45
States / cities
Mobile, Alabama • Tucson, Arizona • Colton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 23, 2026, 7:26 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Post Operative Continuous Active Combination Sex Steroids for the Prevention of Recurrent Endometrioma Formation

NCT00999479
View directory record Official record
Conditions
Endometrioma
Interventions
Norethindrone acetate and ethinyl estradiol tablets, USP, ferrous fumarate (placebo) tablets
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study

NCT01706705
View directory record Official record
Conditions
Cervical Cancer
Interventions
Intracavitary Applicator Placement, Computed Tomography (CT), Magnetic Resonance Imaging (MRI)
Device · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Sep 23, 2026, 7:26 PM EDT